CN112176105B - Special primer for virus BVDV, BRV and BCV one-tube multiplex fluorescence PCR detection and application thereof - Google Patents
Special primer for virus BVDV, BRV and BCV one-tube multiplex fluorescence PCR detection and application thereof Download PDFInfo
- Publication number
- CN112176105B CN112176105B CN202011079561.7A CN202011079561A CN112176105B CN 112176105 B CN112176105 B CN 112176105B CN 202011079561 A CN202011079561 A CN 202011079561A CN 112176105 B CN112176105 B CN 112176105B
- Authority
- CN
- China
- Prior art keywords
- bcv
- brv
- bvdv
- primer
- pcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 title claims abstract description 57
- 238000001514 detection method Methods 0.000 title abstract description 23
- 238000006243 chemical reaction Methods 0.000 claims abstract description 24
- PPBOKXIGFIBOGK-BDTUAEFFSA-N bvdv Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)C(C)C)[C@@H](C)CC)C1=CN=CN1 PPBOKXIGFIBOGK-BDTUAEFFSA-N 0.000 claims abstract 6
- 238000011144 upstream manufacturing Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 10
- 239000013642 negative control Substances 0.000 claims description 8
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- 239000008223 sterile water Substances 0.000 claims description 5
- 238000007403 mPCR Methods 0.000 claims description 4
- 230000010460 detection of virus Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 abstract description 32
- 238000000034 method Methods 0.000 abstract description 21
- 230000035945 sensitivity Effects 0.000 abstract description 7
- 241000607142 Salmonella Species 0.000 abstract description 4
- 241000588724 Escherichia coli Species 0.000 abstract description 3
- 241000701083 Bovine alphaherpesvirus 1 Species 0.000 abstract 1
- 241000711443 Bovine coronavirus Species 0.000 description 49
- 241000702673 Bovine rotavirus Species 0.000 description 46
- 238000003753 real-time PCR Methods 0.000 description 25
- 108020004414 DNA Proteins 0.000 description 18
- 230000003321 amplification Effects 0.000 description 17
- 238000003199 nucleic acid amplification method Methods 0.000 description 17
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 208000003322 Coinfection Diseases 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 238000010586 diagram Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- 108010008529 bovine viral diarrhea virus gp53 Proteins 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101000654245 Homo sapiens Succinate dehydrogenase assembly factor 2, mitochondrial Proteins 0.000 description 1
- 238000007397 LAMP assay Methods 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102100031715 Succinate dehydrogenase assembly factor 2, mitochondrial Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a special primer for virus BVDV, BRV and BCV one-tube multiplex fluorescence PCR detection and application thereof, belonging to the technical field of molecular biology detection. The invention designs the optimal multiple fluorescence PCR reaction condition aiming at the special primer, and the minimum detection limits of the primer and the reaction condition on plasmid standard products of BVDV, BRV and BCV are respectively 1.19 multiplied by 102Copy/. mu.L, 3.89X 101Copy/. mu.L, 3.74X 101The lowest sensitivity is 100 times higher than that of the conventional PCR and the sensitivity is high; the method only specifically amplifies BVDV, BRV and BCV, has no cross reaction with Escherichia coli, salmonella and infectious bovine rhinotracheitis virus, and has strong specificity; the coefficient of variation among groups is less than 1 percent, and the repeatability is good.
Description
Technical Field
The invention belongs to the technical field of molecular biological detection, and particularly relates to a special primer for one-tube multiple fluorescence PCR detection of viruses BVDV, BRV and BCV and application thereof.
Background
In recent years, along with the scale expansion of the dairy cow breeding industry, the incidence rate of calf diarrhea is on a trend of rising year by year, the calf diarrhea seriously affects the growth and development of calves in early stage and the stability of production performance in later stage, the death rate is up to 90%, and the amplification of herds and the benign development of the dairy cow breeding industry are seriously affected. The factors causing calf diarrhea are intricate, wherein the diarrhea caused by infectious viruses is the most serious and is mostly mixed infection, and Bovine Viral Diarrhea Virus (BVDV), Bovine Rotavirus (BRV) and Bovine Coronavirus (BCV) are the most common pathogens. In the clinical diagnosis process, the three pathogenies have relatively similar clinical symptoms and are often mixed to infect, thereby causing great difficulty in the accurate diagnosis of the pathogeny, having rapid propagation, great harm and no specific drug treatment, and causing great economic loss to the dairy cow industry.
At present, BVDV, BRV and BCV diagnosis methods mainly comprise pathogen cell separation, electron microscopy, single PCR, multiple PCR, ELISA, gene chip, loop-mediated isothermal amplification and other methods, but the detection methods have obvious limitations. The real-time fluorescence quantitative PCR has the advantages of simple operation, higher sensitivity, good repeatability, short time consumption and the like, and is widely applied to detection in a laboratory. The real-time fluorescent quantitative PCR has two fluorescent dye methods and a TaqMan probe method, the most common fluorescent dye method can be used for carrying out multiple gene detection, the requirement of detecting various nucleic acid sequences by the same reaction tube can be met, the time consumption is shorter, and meanwhile, the fluorescent quantitative PCR overcomes the defects of the conventional PCR in the aspects of sensitivity, efficiency, pathogen content measurement and the like. Therefore, it is urgently needed to establish a multiplex fluorescence quantitative PCR method capable of simultaneously detecting the three pathogens, which provides certain help for disease prevention and control.
Disclosure of Invention
In order to solve the technical problems, the invention provides a special primer for one-tube multiple fluorescence PCR detection of viruses BVDV, BRV and BCV.
The invention designs the following specific primers by respectively referring to highly conserved sequences of BVDV E2 gene, BRVVP6 gene and BCVN gene in GenBank:
BVDV upstream primer SEQ ID NO. 1: 5'-GGTCATAGCTCTCGACACCA-3', respectively;
BVDV downstream primer SEQ ID NO. 2: 5'-GAGCACGTATCTACCACCCA-3', respectively;
BRV upstream primer SEQ ID NO. 3: 5'-AGACAAAGAACGGGTTTCACA-3', respectively;
BRV downstream primer SEQ ID NO. 4: 5'-AGTCAAATCCAGCGACCTGA-3', respectively;
BCV upstream primer SEQ ID NO. 5: 5'-GCGTCCTCTGGAAATCGTTC-3', respectively;
BCV downstream primer SEQ ID NO. 6: 5'-AGCAGTTTGCTTGGGTTGAG-3' are provided.
The reaction system for performing one-tube multiplex fluorescent PCR by using the primers is 25 mu L: PerfectStartTM Green SuperMix 12.5. mu.L, BVDV, BRV, BCV upstream and downstream primers 0.5. mu.L respectively, test sample 1.0. mu.L, deionized water 3.5. mu.L.
Further, the reaction procedure of the one-tube multiplex fluorescence PCR is 95 ℃ for 5min, 95 ℃ for 20s, 55 ℃ for 20s, and 72 ℃ for 20s, and the total number of the reaction procedures is 45 cycles.
Furthermore, sterile water was set as a negative control during one-tube multiplex PCR.
The invention also provides application of the special primer in preparation of products for detecting viruses BVDV, BRV and BCV.
Compared with the prior art, the invention has the following beneficial effects:
the invention provides a special primer and corresponding optimal reaction conditions, and the minimum detection limits of the special primer on plasmid standard products of BVDV, BRV and BCV are respectively 1.19 multiplied by 102Copy/. mu.L, 3.89X 101Copy/. mu.L, 3.74X 101The lowest sensitivity is 100 times higher than that of the conventional PCR and the sensitivity is high; the method only specifically amplifies BVDV, BRV and BCV, has no cross reaction with E.coli, Salmonella and IBRV, and has strong specificity; the coefficient of variation among groups is less than 1 percent, and the repeatability is good. The multiplex fluorescence quantitative PCR detection method established by the invention provides a rapid, sensitive and specific technical means for the clinical detection and epidemiological investigation of BVDV, BRV and BCV.
Drawings
FIG. 1 is a diagram of the electrophoresis of the PCR gel in example 2.
FIG. 2a is a standard curve diagram of the BVDV recombinant plasmid in example 3.
FIG. 2b is a standard curve of the BRV recombinant plasmid in example 3.
FIG. 2c is a standard graph of the BCV recombinant plasmid of example 3.
FIG. 3a is a melting curve diagram of the recombinant plasmid of BVDV in example 4.
FIG. 3b is a melting curve diagram of the BRV recombinant plasmid in example 4.
FIG. 3c is a melting profile of the BCV recombinant plasmid in example 4.
FIG. 4a is a fluorescent quantitative PCR amplification result of BVDV standard in example 5.
FIG. 4b is a graph of the results of fluorescent quantitative PCR amplification of the BRV standard in example 5.
FIG. 4c is a graph of the results of fluorescent quantitative PCR amplification of the BCV standard in example 5.
FIG. 5 is a graph showing the results of ordinary PCR assay of different dilutions of the BVDV, BRV and BCV standards in example 5.
FIG. 6 is a graph showing the results of fluorescent quantitative PCR amplification in example 6.
FIG. 7 is a dissolution chart of the results of the clinical sample BVDV + BRV + BCV mixed infection assay of example 8.
FIG. 8 is a dissolution chart of the results of the clinical sample BVDV + BCV mixed infection assay in example 8.
Detailed Description
The main reagents used in the following examples are as follows: DL1000 DNA Marker and DL2000 DNA Marker are purchased from Dalibao bioengineering GmbH; viral genome RNA extraction kit (paramagnetic particle method) was purchased from Jiangsu Shuiches Biotechnology Ltd; agarose was purchased from Biowest; superNucleic acid gel dyes (S2001) were purchased from USlnc corporation; 2 × EsTaqMasterMix, PerfectStartTMThe Green qPCR Supermix kit is purchased from Beijing Quanyujin Biotechnology Co., Ltd; pUC57 was purchased from Bao bioengineering (Dalian) Co., Ltd; SDH5 α competent cells were purchased from beijing hologold biotechnology limited; plasmid mini-extraction kit was purchased from BIOMIGA, USA; the SanPrep column type DNA gel recovery kit is purchased from Biotechnology engineering (Shanghai) GmbH.
Example 1
3 pairs of specific primers are designed by using DNA Star and Primer5.0 software according to BVDV (MK170077), BRV (MNo47454) and BCV (MK903505) reference strain sequences published in GenBank, and are used for amplifying BVDV E2 gene, BRVVP6 gene and BCV N gene. The primers were synthesized by Changchun Kumei bioengineering GmbH, and the sequences of the primers are shown in Table 1.
TABLE 1 PCR primer sequences
Example 2
The preparation of BVDV, BRV and BCV recombinant plasmid standard comprises the following steps:
(1) and (3) treating a clinical sample: collecting 150 parts of fresh diarrhea and excrement samples from 10 cattle farms in Shijiazhuang Xinle and Xinji areas, respectively adding the 150 parts of fresh excrement samples into a sterilized centrifugal tube containing 5ml of PBS (phosphate buffer solution) with pH7.2, repeatedly oscillating for 1min, centrifuging for 10min at 5000r/min, and taking supernatant; extracting viral nucleic acid by using a full-automatic nucleic acid extractor according to the instruction of a viral genome RNA extraction kit (magnetic bead method), carrying out reverse transcription on the extracted nucleic acid product by using a reverse transcription kit to obtain cDNA, and storing at-20 ℃ for later use.
(2) The cDNAs of BVDV, BRV and BCV were amplified by PCR using the specific primers designed in example 1, respectively, and sterile deionized water was used as a negative control.
Reaction system: 2 × EsTaqMasterMix reaction solution 10 μ L, ddH2O6. mu.L, 1. mu.L of each of the upper and lower primers, and 2. mu.L of the DNA template, 20. mu.L in total. Reaction procedure: 5min at 94 ℃; 30s at 94 ℃; 30s at 55 ℃; 30s at 72 ℃; a total of 35 cycles; 7min at 72 ℃.
(3) Purifying and recovering the amplified PCR product, respectively connecting the three recovered fragments to a pUC57 vector, transforming DH5 alpha competent cells, coating a plate, screening positive clone plasmids, culturing, extracting recombinant plasmids for PCR, enzyme digestion and sequencing identification, wherein agarose gel electrophoresis is carried out after the PCR of the recombinant plasmids, and the result is shown in figure 1 (wherein M: DL1000 Marker, 1: negative control, 2: BVDV recombinant plasmid, 3: BRV recombinant plasmid and 4: BCV recombinant plasmid), the size of the amplified target fragment is respectively 280bp, 151bp and 111bp, and the size is equal to that of the pre-amplified target fragmentThe results were consistent. The concentrations of BVDV, BRV and BCV recombinant plasmids are respectively 0.05 ng/mu L, 1.67 ng/mu L and 1.60 ng/mu L by using the NanoDrop 2000 to determine the correctly identified positive recombinant plasmids, and the copy numbers of the recombinant plasmids are respectively 1.19 multiplied by 10 through conversion of a formula10Copy/. mu.L, 3.89X 1010Copy/. mu.L, 3.74X 1010Copies/. mu.L, were used as plasmid standards, respectively.
The copy number is calculated as follows: copy number plasmid concentration × 6.02 × 1023/(660X total length of plasmid).
Single fluorescent quantitative PCR reaction: the prepared plasmid standard substances are respectively subjected to 10-fold gradient dilution and then subjected to PCR amplification. Three replicates of each gradient were performed and the amplification results were analyzed to establish respective standard curves. And simultaneously analyzing the melting curve of the primer to eliminate the interference of primer dimer and nonspecific amplification. The reaction system is 15 μ L: PerfectStartTM Green SuperMix 7.5. mu.L, upstream and downstream primers 0.5. mu.L, template 1.0. mu.L, and deionized water 4.5. mu.L. Reaction conditions are as follows: 5min at 95 ℃; 20s at 95 ℃; at 56 ℃ for 20 s; 20s at 72 ℃; a total of 45 cycles; meanwhile, sterile water is set as a negative control.
Optimizing the reaction conditions of the multiple fluorescent quantitative PCR: and optimizing the reaction temperature and the reaction system of the multiple fluorescent quantitative PCR and determining the reaction conditions. Performing multiple fluorescent quantitative PCR amplification in the same reaction system by using a standard substance diluted in a gradient manner as a template, respectively optimizing annealing temperature (52 ℃, 53 ℃, 54 ℃, 55 ℃, 56 ℃, 57 ℃ and 58 ℃), primer concentration (final concentration is (0.2 muL, 0.3 muL, 0.4 muL, 0.5 muL, 0.6 muL, 0.7 muL and 0.8 muL), judging results when Ct value is less than or equal to 45 cycles to determine the optimal reaction condition of the fluorescent quantitative PCR, wherein the optimal reaction system is 25 muL of PerfectStartTM Green SuperMix 12.5 muL, BVDV, BRV, BCV upstream and downstream primers are 0.5 muL respectively, BVDV, BRV and BCV templates are 1.0 muL respectively, deionized water is 3.5 muL, reaction program is 95 ℃ for 5min, 95 ℃ for 20s, 55 ℃ for 20s, 72 ℃ for 20s, and 45 cycles in total, and sterile water negative control is set at the same time.
Example 3
Diluting the three prepared plasmid standard substances according to a gradient of 10 times, and taking the concentrationInterval of 107-100After copying/mu L, respectively carrying out fluorescent quantitative PCR amplification, wherein the BVDV recombinant plasmid standard substance is at the concentration of 107-102Between copies/. mu.L, at a concentration of 10 for BRV, BCV recombinant plasmid standards7-101Fluorescence signals can be detected between copies/. mu.L, and a standard curve of fluorescence quantitative PCR can be obtained by analyzing with automatic system analysis software, wherein the logarithm of the copy number is used as a vertical coordinate, the Ct value is used as a horizontal coordinate, and the results are shown in FIGS. 2a-2c, wherein FIG. 2a is the standard curve of BVDV recombinant plasmid, FIG. 2b is the standard curve of BRV recombinant plasmid, and FIG. 2c is the standard curve of BCV recombinant plasmid. As can be seen from FIGS. 2a-2c, BVDV is 107-102The copy/. mu.L range of BRV and BCV is 107-101The amplification efficiency of the standard substance constructed in the range of copy/. mu.L is more than 90 percent, and the correlation coefficient R2The values are all above 0.99, which indicates that the initial template number and the Ct value of various standards show good linear relation.
The linear equation for the copy number (x) and Ct value (y) obtained is: BVDV, y ═ 3.911x +40.21, R2=0.995;
BRV,y=-3.657x+37.64,R2=0.992;BCV,y=-3.647x+37.73,R2=0.997。
Example 4
The melting curves of the respective dilutions of the BVDV, BRV, BCV standards had one and only one peak, with the melting temperature of BVDV E2 gene being about 85 ℃, as shown in fig. 3a, the melting temperature of BRVVP6 gene being about 83 ℃, as shown in fig. 3b, and the melting temperature of BCVN gene being about 84 ℃, as shown in fig. 3 c.
Example 5
The BVDV, BRV and BCV standard is diluted by 10 times of gradient, and fluorescence quantitative PCR amplification is carried out according to the established reaction conditions, the results are shown in figures 4a-4c, wherein figure 4a is a diagram of the fluorescence quantitative PCR amplification results of the BVDV standard (1-6: 10 in the figure)7-102Copy/. mu.L; 7-8: 101-100Copy/. mu.L), FIG. 4b is a graph of the results of fluorescent quantitative PCR amplification of BRV standards (1-7 in the figure: 107-101Copy/. mu.L; 8: 100Copy/. mu.L), FIG. 4c isGraph of fluorescent quantitative PCR amplification results of BCV standard (1-7: 10 in the figure)7-101Copy/. mu.L; 8: 100Copy/. mu.L). As can be seen from FIGS. 4a-4c, the lowest detection limit of BVDV is 102Copy/. mu.L, minimum detection limits of BRV and BCV of 101Copies/. mu.L.
BVDV, BRV, BCV standards were diluted 10-fold gradiently and tested by the general PCR method, the results are shown in fig. 5, where M: DL2000 Marker, 1-8: 107-100At a copy/. mu.L, the minimum detection limit of BVDV was found to be 104Copy/. mu.L, minimum detection limits of BRV and BCV of 103Copy/. mu.L; compared with the common multiplex PCR, the sensitivity of the established multiplex fluorescent quantitative PCR method is greatly improved.
Example 6
Using BVDV, BRV, BCV standards as positive controls, genomic DNA of e.coli, Salmonella, IBRV and water as templates, and performing fluorescent quantitative PCR amplification according to the established reaction conditions, the results are shown in fig. 6, wherein 1-3: BVDV, BRV and BCV recombinant plasmids; 4-7: coli, Salmonella, IBRV genomic DNA and water. As can be seen from FIG. 6, the amplification curves of the 3 types of standards were detected, but no amplification curve was observed for any of the other pathogens and the negative control, indicating that the method has good specificity.
Example 7
BVDV, BRV and BCV recombinant plasmids are respectively diluted by 10 times and mixed in equal proportion, and 3 concentration gradients (final concentration is 10 respectively)6Copy/. mu.L, 105Copy/. mu.L, 104Copies/. mu.L) of plasmid mixture, while setting sterile water negative control. Repeatedly detecting for 3 times by using the established fluorescent quantitative PCR method, and performing an intra-group repeatability test; the test results are counted and the repeatability of the method is evaluated, wherein the results are shown in table 2.
TABLE 2 repeatability results of multiplex fluorescent quantitative PCR
As can be seen from Table 2, the intra-group coefficient of variation is less than 1%, and the inter-group coefficient of variation is less than 1%, indicating that the multiple fluorescence quantitative detection method established by the test has good repeatability.
Example 8
The results of testing 150 clinical stool samples collected using the established method are shown in Table 3, wherein the clinical sample BVDV + BRV + BCV mixed infection test results are shown in FIG. 7, and the clinical sample BVDV + BCV mixed infection test results are shown in FIG. 8.
As shown in Table 3, the mixed infection positive rate of the three viruses detected by multiplex quantitative PCR was 12.0% (18/150), and the mixed infection positive rate of the three viruses detected by ordinary PCR was 10.0% (15/150). The coincidence rate of the detection of the two methods is 83.3 percent. The detection method established by the test is more sensitive and can be applied to clinical detection.
TABLE 3 test results for clinical diarrhea samples
Comparative example 1
The following 3 pairs of primers SEQ ID NO.7-12 were used in place of the primers SEQ ID NO.1-6 used in example 8, and the results are shown in Table 4.
BVDV upstream primer SEQ ID NO. 7: CTTGGTGCGAAGATGGGAAG, respectively;
BVDV downstream primer SEQ ID NO. 8: ATCACATGGGCAGAGTCCAA are provided.
BRV upstream primer SEQ ID NO. 9: TCAGGTCGCTGGATTTGACT, respectively;
BRV downstream primer SEQ ID NO. 10: GTACCATGTAGTCGCTCCGT are provided.
BCV upstream primer SEQ ID NO. 11: GATCTACTTCACGCGCATCC, respectively;
BCV downstream primer SEQ ID NO. 12: GTGGCTTAGTGGCATCCTTG are provided.
TABLE 4 multiplex fluorescent quantitation PCR clinical sample detection results
Pathogens | Number of positive samples | The positive rate% |
BVDV+BRV+ |
12 | 8 |
BVDV+ |
6 | 4 |
BRV+BCV | 35 | 23.3 |
BVDV+ |
6 | 4 |
BVDV | 0 | 0 |
|
5 | 3.3 |
|
2 | 1.3 |
Total up to | 66 | 43.9 |
The primers SEQ ID NO.1-6 provided by the invention have higher detection coincidence rate than the primers SEQ ID NO.7-12 in the comparison example 1.
The above-described embodiments are only intended to illustrate the preferred embodiments of the present invention, and not to limit the scope of the present invention, and various modifications and improvements made to the technical solution of the present invention by those skilled in the art without departing from the spirit of the present invention should fall within the protection scope defined by the claims of the present invention.
Sequence listing
<110> university of agriculture in Hebei
Special primer for one-tube multiple fluorescence PCR detection of <120> viruses BVDV, BRV and BCV and application thereof
<130> 2020.9.2
<141> 2020-10-09
<160> 12
<170> SIPOSequenceListing 1.0
<210> 1
<211> 20
<212> DNA
<213> Artificial sequence ()
<400> 1
<210> 2
<211> 20
<212> DNA
<213> Artificial sequence ()
<400> 2
<210> 3
<211> 21
<212> DNA
<213> Artificial sequence ()
<400> 3
agacaaagaa cgggtttcac a 21
<210> 4
<211> 20
<212> DNA
<213> Artificial sequence ()
<400> 4
<210> 5
<211> 20
<212> DNA
<213> Artificial sequence ()
<400> 5
gcgtcctctg gaaatcgttc 20
<210> 6
<211> 20
<212> DNA
<213> Artificial sequence ()
<400> 6
<210> 7
<211> 20
<212> DNA
<213> Artificial sequence ()
<400> 7
<210> 8
<211> 20
<212> DNA
<213> Artificial sequence ()
<400> 8
<210> 9
<211> 20
<212> DNA
<213> Artificial sequence ()
<400> 9
<210> 10
<211> 20
<212> DNA
<213> Artificial sequence ()
<400> 10
<210> 11
<211> 20
<212> DNA
<213> Artificial sequence ()
<400> 11
gatctacttc acgcgcatcc 20
<210> 12
<211> 20
<212> DNA
<213> Artificial sequence ()
<400> 12
Claims (5)
1. The special primer for one-tube multiple fluorescence PCR detection of viruses BVDV, BRV and BCV is characterized in that the sequence of the special primer is shown as SEQ ID NO.1-6, wherein:
BVDV upstream primer SEQ ID NO. 1: 5'-GGTCATAGCTCTCGACACCA-3', respectively;
BVDV downstream primer SEQ ID NO. 2: 5'-GAGCACGTATCTACCACCCA-3', respectively;
BRV upstream primer SEQ ID NO. 3: 5'-AGACAAAGAACGGGTTTCACA-3', respectively;
BRV downstream primer SEQ ID NO. 4: 5'-AGTCAAATCCAGCGACCTGA-3', respectively;
BCV upstream primer SEQ ID NO. 5: 5'-GCGTCCTCTGGAAATCGTTC-3', respectively;
BCV downstream primer SEQ ID NO. 6: 5' -AGCAGTTTGCTTGGGTTGAG-3.
2. The special primer as claimed in claim 1, wherein the reaction system for performing one-tube multiplex fluorescence PCR with the special primer is 25 μ L: PerfectStartTM Green SuperMix 12.5. mu.L, BVDV, BRV, BCV upstream and downstream primers 0.5. mu.L respectively, test sample 1.0. mu.L, deionized water 3.5. mu.L.
3. The special primer as claimed in claim 2, wherein the reaction program of the one-tube multiplex PCR is 95 ℃ for 5min, 95 ℃ for 20s, 55 ℃ for 20s, 72 ℃ for 20s, and 45 cycles.
4. The primer set as claimed in claim 3, wherein the PCR is performed in a tube of multiplex PCR with a negative control of sterile water.
5. Use of the special primers according to any one of claims 1 to 4 for the preparation of products for detecting viruses BVDV, BRV and BCV.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011079561.7A CN112176105B (en) | 2020-10-10 | 2020-10-10 | Special primer for virus BVDV, BRV and BCV one-tube multiplex fluorescence PCR detection and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011079561.7A CN112176105B (en) | 2020-10-10 | 2020-10-10 | Special primer for virus BVDV, BRV and BCV one-tube multiplex fluorescence PCR detection and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112176105A CN112176105A (en) | 2021-01-05 |
CN112176105B true CN112176105B (en) | 2022-05-31 |
Family
ID=73948796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011079561.7A Active CN112176105B (en) | 2020-10-10 | 2020-10-10 | Special primer for virus BVDV, BRV and BCV one-tube multiplex fluorescence PCR detection and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112176105B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110643739B (en) * | 2019-10-15 | 2023-08-04 | 云南省畜牧兽医科学院 | One-step triple RT-PCR detection primer and kit for distinguishing CHUV, BCV and DAV |
CN113136455A (en) * | 2021-04-23 | 2021-07-20 | 河北农业大学 | Multiplex fluorescence quantitative PCR method and kit for detecting BVDV, BCoV, BRV and IBRV |
CN114774583A (en) * | 2022-03-16 | 2022-07-22 | 新疆农业大学 | Kit for simultaneously detecting BCoV and BRV and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101063176A (en) * | 2007-05-23 | 2007-10-31 | 山东奥克斯生物技术有限公司 | Dual RT-PCR method and special reagent case for checking cattle rotavirus and cattle virus diarrhea virus simultaneously |
CN108913815B (en) * | 2018-08-28 | 2021-12-10 | 河南省农业科学院畜牧兽医研究所 | Primer group for detecting bovine norovirus and bovine coronavirus and dual RT-PCR method |
KR102061896B1 (en) * | 2018-11-20 | 2020-01-09 | 대한민국 | PNA probe for detecting bovine viral diarrhea virus genetic type and a method for detecting bovine viral diarrhea virus genetic type using the same |
CN110079637B (en) * | 2019-06-14 | 2023-06-20 | 内蒙古民族大学 | Bovine rotavirus, coronavirus and viral diarrhea virus multiplex RT-PCR detection method |
-
2020
- 2020-10-10 CN CN202011079561.7A patent/CN112176105B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN112176105A (en) | 2021-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112176105B (en) | Special primer for virus BVDV, BRV and BCV one-tube multiplex fluorescence PCR detection and application thereof | |
CN106947838B (en) | African swine fever virus non-structural gene real-time fluorescence LAMP (loop-mediated isothermal amplification) detection primer group, kit and detection method | |
CN110004240B (en) | Real-time fluorescence detection kit and test strip detection kit for mycoplasma gallisepticum based on RPA and application of kit and test strip detection kit | |
CN110699489B (en) | Real-time fluorescence PCR detection primer probe set, kit and method for African swine fever virus CD2V gene | |
CN105907890B (en) | Primer, probe and method for quickly distinguishing HP-PRRS vaccine GDr180 strain and wild strain | |
CN113249517A (en) | Primer, probe and kit for real-time fluorescent quantitative PCR (polymerase chain reaction) detection of bovine plague | |
CN114085929B (en) | Kit for detecting African swine fever virus wild strain and vaccine strain | |
CN114634996B (en) | Primer probe combination and kit for detecting bovine respiratory disease and application of primer probe combination and kit | |
CN113174446A (en) | One-step double RT-PCR detection method for bovine viral diarrhea virus typing | |
CN112695137A (en) | PMA-qPCR detection method of porcine pseudorabies virus | |
CN112458208B (en) | Kit and method for detecting bovine sarcoidosis virus | |
CN117004777A (en) | RPA composition for detecting mandarin fish rhabdovirus, application thereof and detection method | |
CN116426690A (en) | Primer composition for detecting gene causing boundary disease virus and application thereof | |
CN112626278B (en) | Primer and probe for identifying canine distemper virus wild strain and vaccine strain and application | |
CN115976272A (en) | TaqMan fluorescent quantitative PCR method for rapidly detecting prawn hemangiocyte iridovirus | |
CN115612753A (en) | Method for detecting aleuti, enteritis and canine distemper | |
CN115094164A (en) | Multiple qPCR (quantitative polymerase chain reaction) kit and detection method for ASFV (advanced specific immunodeficiency syndrome) with different gene deletion types | |
CN114592089A (en) | Triple TaqMan fluorescent quantitative PCR kit for simultaneously detecting three circovirus | |
CN113493850A (en) | PCR primer probe group and kit for real-time fluorescent quantitative detection of toxoplasma gondii and eperythrozoon of pig and detection method thereof | |
CN110157836B (en) | Primer, probe and method for detecting IBRV and BVDV | |
CN113136455A (en) | Multiplex fluorescence quantitative PCR method and kit for detecting BVDV, BCoV, BRV and IBRV | |
CN113151586A (en) | Primer combination, kit and method for detecting and identifying porcine pseudorabies virus type I and type II | |
CN114540538A (en) | Detection kit for simultaneously and quantitatively detecting EHV-1 and EHV-4 and application thereof | |
CN112063757A (en) | Primer and kit for detecting African swine fever virus and application of primer and kit | |
CN115976273B (en) | Dual fluorescence PCR detection kit for identifying African swine fever virus genes type I and type II |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |